SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001104659-21-000105
Filing Date
2021-01-04
Accepted
2021-01-04 08:10:25
Documents
2
Period of Report
2021-01-01

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm2039608-1_3seq1.html 3  
1 OWNERSHIP DOCUMENT tm2039608-1_3seq1.xml 3 10319
2 EXHIBIT 24 tm2039608d1_ex24.htm EX-24 5195
  Complete submission text file 0001104659-21-000105.txt   17136
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Issuer) CIK: 0000744218 (see all company filings)

IRS No.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2835 In Vitro & In Vivo Diagnostic Substances

Mailing Address C/O CELLDEX THERAPEUTICS, INC. 53 FRONTAGE ROAD, SUITE 220 HAMPTON NJ 08827
Business Address
Jimenez Freddy A. (Reporting) CIK: 0001838114 (see all company filings)

Type: 3 | Act: 34 | File No.: 000-15006 | Film No.: 21500235